DB05757InvestigationalSmall molecule
DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP-...
- Primary indication
- Investigated for use/treatment in ocular hypertension.Curator reviewed
- Code names
- DNB-001
What you can answer from here — as of April 02, 2025
Which companies are running trials of DNB-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account